$EQBK

Equity Bancshares Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings

Equity Bancshares (NYSE:EQBK) is set to report Q2 earnings after the close on Tuesday, July 14. Analysts expect EPS of $1.23 versus 93 cents a year ago, and revenue of $85.07M versus $58.38M last year, according to Benzinga Pro. The article notes EQBK shares closed at $50.20 after rising 2.5% on Wednesday.

Original reporting
Published Jul 2, 2026, 12:45 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 2, 2026, 1:01 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$EQBK
Neutral
medium confidence
Mentioned
$EQBK
Relevance
5/10
alphai data visualization · based on benzinga.com
Decision brief

The 30-second read

$EQBKNeutralMed
01

Why it matters

The actionable element is the earnings timing plus the consensus EPS/revenue targets, which can be used to calibrate options/volatility expectations into the print.

02

Market read

Traders can use the stated consensus EPS ($1.23) and revenue ($85.07M) to benchmark the upcoming after-hours earnings reaction.

03

What to watch

The article omits key drivers (net interest margin, credit quality, deposit costs, guidance) that typically determine bank earnings reactions.

Relevance 5/10Novelty 4/10Timing: Ahead of EQBK’s after-hours Q2 earnings release on Tuesday, July 14.

Background

EQBK posted better-than-expected first-quarter earnings on April 14, and shares rose 2.5% to $50.20 on Wednesday.

Company-level read

Ticker impact

$EQBKNeutralMedium confidence
Context

Equity Bancshares (EQBK) is set to report Q2 earnings after the close July 14, with consensus EPS and revenue expectations cited.

Expected impact

Near-term volatility likely increases into the July 14 after-hours earnings release; direction depends on the eventual EPS/revenue vs consensus.

Evidence & confidence

The article provides the earnings date and consensus figures but no new company-specific fundamentals beyond what’s typically known pre-print.

Market effects

Limited: this is a single-bank earnings calendar/expectations item with no broader sector datapoint.

Minimal: the article provides no Kansas/regional banking macro or peer read-across.

Low: no cross-market or international linkage is discussed.

Counterpoint

Consensus-beating risk is not addressed; without guidance details, the setup may be more about positioning than fundamentals.

Key entities

  • Equity Bancshares, Inc.

    Subject of the article; scheduled to release Q2 earnings after the close on July 14.

Related articles

$EQBKMed

Equity Bancshares Q2 Earnings Call Highlights

Equity Bancshares (NYSE:EQBK) reported Q2 updates on margins, loan growth, deposits, income, expenses, credit quality and capital. Management said loan production closed $315M, with average loan rate 6.56% and pipeline $1.6B. Deposits were flat. Non-interest income rose to $10.3M; expenses fell to $46.9M. Non-performing assets rose to 86 bps; tangible common equity was 9.07%.

$EQBKMed

EQUITY BANCSHARES INC (EQBK): Results of Operations and Financial Condition

EQUITY BANCSHARES INC (EQBK) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 eqbk-ex99_1.htm EX-99.1 EX-99.1 Equity Bancshares, Inc. Exhibit 99.1 PRESS RELEASE Equity Bancshares, Inc. Second Quarter Results Highlighted by Strong Earnings Momentum and Margin Expansion EPS of $1.27 and Core EPS of $1.41 Reflects Franchise Earning Power WICHITA, Ka

$VSXYMedAI 8/10

Should you buy Victoria’s Secret stock after today’s sharp selloff?

Victoria’s Secret (VSXY) shares fell 5.67% premarket after Q3 operating income guidance missed estimates, though full-year outlook improved. Q2 revenue was $1.61B, slightly below consensus, while adjusted EPS beat estimates. Management cited increased marketing investment and one-time tariff refunds as factors. The stock has gained 269.22% over one year but faces technical and margin concerns.

$WLYMed

JOHN WILEY & SONS, INC. (WLY): Results of Operations and Financial Condition

JOHN WILEY & SONS, INC. (WLY) filed an SEC Form 8-K — Results of Operations and Financial Condition. Wiley Reports First Quarter 2027 Results; Q1 in line with expectations and full year outlook reaffirmed Strength in Research and AI offset by prior year comparison and softness in Learning – Emerald integration ahead of schedule September 3, 2026 - Hoboken, NJ – Wiley (NYSE: WLY)

$OCULMedAI 8/10

Ocular Therapeutix (OCUL): Faster Path To Approval Comes With Rising Costs

Ocular Therapeutix (OCUL) reported Q2 2026 results, highlighting AXPAXLI's progress for wet age-related macular degeneration. The FDA confirmed the NDA filing timeline, with potential for a faster review. Costs rose, with R&D at $54.1M, marketing at $17.3M, and net loss widening to $78.8M. Cash reserves decreased to $598.6M. AXPAXLI's data suggests fewer patient injections, and early market research shows high adoption potential. Institutional interest grew, but short interest remains high.

$HPEHighAI 8/10

HPE raises fiscal 2026 sales forecast on AI server demand

HPE raised its fiscal 2026 revenue growth forecast to 34-37% (up from 29-33%) and fiscal 2027 outlook to 13-17% (up from 8-12%) due to AI server demand. Q3 revenue rose 34% YoY to $12.2B, with server and networking revenue up 35% and 75% respectively. Adjusted EPS forecast for FY2026 raised to $3.75-$3.85. HPE stock fell 5% in extended trading. Supply constraints persist, with inventory up to $11.82B. HPE signed a $3.5B agreement with a cloud provider and expanded partnership with Oracle.